{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:21:12Z","timestamp":1776234072814,"version":"3.50.1"},"reference-count":34,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Paradoxical psoriasis (PP) is a known adverse event of anti\u2010tumor necrosis factor (anti\u2010TNF) agents in hidradenitis suppurativa (HS), yet evidence regarding its management remains limited. The objective was to assess the effectiveness of interleukin\u201017 inhibitors (IL\u201017i) in treating anti\u2010TNF\u2010induced PP in patients with HS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter retrospective study included 40 adults with HS who developed PP during anti\u2010TNF therapy and were subsequently treated with IL\u201017i. Outcomes for PP were measured using the Physician's Global Assessment (PGA); HS severity was evaluated using the International Hidradenitis Suppurativa Severity Score System\u00a0(IHS4) and Hurley scores. Paired comparisons were performed using the Wilcoxon signed\u2010rank or McNemar's test, as appropriate. Multivariate analysis was performed using LASSO\u2010regularized logistic regression. Missing data were managed by multiple imputation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the patients, 27.5% achieved a clinically meaningful PP response, while 45% experienced worsening. Female sex, older age at HS onset, and prior exposure to secukinumab were associated with nonresponse. Conversely, HS severity improved significantly in 70% of patients (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IL\u201017i showed limited effectiveness for anti\u2010TNF\u2010induced PP in HS, though improvement in hidradenitis was observed.<\/jats:p>\n                    <jats:p>\n                      <jats:boxed-text content-type=\"graphic\" position=\"anchor\">\n                        <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" mimetype=\"image\/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic\/ijd70420-gra-0001-m.png\">\n                          <jats:alt-text>image<\/jats:alt-text>\n                        <\/jats:graphic>\n                      <\/jats:boxed-text>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ijd.70420","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:39:31Z","timestamp":1776231571000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Limited Effectiveness of\n                    <scp>IL<\/scp>\n                    \u201017 Inhibitors for Anti\u2010\n                    <scp>TNF<\/scp>\n                    \u2010Induced Psoriasis in Hidradenitis Suppurativa: A Multicenter Retrospective Study"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9621-8538","authenticated-orcid":false,"given":"Leonardo","family":"Basc\u00f3n","sequence":"first","affiliation":[{"name":"Department of Dermatology Hospital General de Granollers  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8373-4303","authenticated-orcid":false,"given":"Juan Jos\u00e9","family":"Lluch\u2010Galcer\u00e1","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital General de Granollers  Barcelona Spain"},{"name":"Departament de Medicina Universitat Aut\u00f2noma de Barcelona (UAB)  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Mora\u2010Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitari Germans Trias i Pujol. IGTP  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9482-1621","authenticated-orcid":false,"given":"J\u00falia","family":"Verdaguer\u2010Faja","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitari Germans Trias i Pujol. IGTP  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8432-0954","authenticated-orcid":false,"given":"Sof\u00eda","family":"Haselgruber","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen de Las Nieves, Ibs  Granada Spain"},{"name":"Departamento de Dermatolog\u00eda Universidad de Granada, Ibs  Granada Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6882-2113","authenticated-orcid":false,"given":"Alejandro","family":"Molina\u2010Leyva","sequence":"additional","affiliation":[{"name":"Hospital Universitario Virgen de Las Nieves, Ibs  Granada Spain"},{"name":"Departamento de Dermatolog\u00eda Universidad de Granada, Ibs  Granada Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Sin\u2010Soler","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitari Parc Taul\u00ed  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3325-6785","authenticated-orcid":false,"given":"Patricia","family":"Garbayo\u2010Salmons","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitari Parc Taul\u00ed  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00falia","family":"Mercader\u2010Salvans","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitario de Canarias  Tenerife Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vania Lukoviek","family":"Araya","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitario de Canarias  Tenerife Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Fern\u00e1ndez\u2010Crehuet","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitario Reina Sof\u00eda  C\u00f3rdoba Spain"},{"name":"Maimonides Institute for Biomedical Research of C\u00f3rdoba (IMIBIC)  C\u00f3rdoba Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7906-7570","authenticated-orcid":false,"given":"Laura","family":"Parra\u2010Navarro","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital del Mar, Parc de Salut Mar  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Martin\u2010Ezquerra","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital del Mar, Parc de Salut Mar  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Martin\u2010Poch","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitari Sagrat Cor, Grupo Quir\u00f3nsalud  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Carrascosa","sequence":"additional","affiliation":[{"name":"Departament de Medicina Universitat Aut\u00f2noma de Barcelona (UAB)  Barcelona Spain"},{"name":"Department of Dermatology Hospital Universitari Germans Trias i Pujol. IGTP  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"Sampayo\u2010Cordero","sequence":"additional","affiliation":[{"name":"Department of Research and Innovation Hospital General de Granollers  Granollers Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Roman\u00ed","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital General de Granollers  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Guilabert Vidal","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital General de Granollers  Barcelona Spain"},{"name":"Universitat Internacional de Catalunya  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"6","key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1159\/000533370","article-title":"Adalimumab\u2010Induced Paradoxical Psoriasis Treated With Biologics Targeting the IL\u201017\/IL\u201023 Axis in Patients With Hidradenitis Suppurativa","volume":"239","author":"Tsiogka A.","year":"2023","journal-title":"Dermatology"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15866"},{"issue":"6","key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jaad.2025.02.015","article-title":"Patients With PSOriasis and Suppurative Hidradenitis (PSO\u2010SH) Share Genetic Risk Factors and Are at Risk of Increased Morbidity","volume":"92","author":"Wiala A.","year":"2025","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"5","key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1159\/000511868","article-title":"Coprevalence of Hidradenitis Suppurativa and Psoriasis: Detailed Demographic, Disease Severity and Comorbidity Pattern","volume":"237","author":"Pinter A.","year":"2021","journal-title":"Dermatology"},{"issue":"6","key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.jaad.2020.06.081","article-title":"Family History of Psoriasis, Psychological Stressors, and Tobacco Use Are Associated With the Development of Tumor Necrosis Factor\u2010\u03b1 Inhibitor\u2010Induced Psoriasis: A Case\u2010Control Study","volume":"83","author":"Ya J.","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"key":"e_1_2_12_7_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.847160","article-title":"Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti\u2010TNF Therapy: Systematic Review With Meta\u2010Analysis","volume":"13","author":"Xie W.","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"7","key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.13352","article-title":"Paradoxical Psoriasis in a Large Cohort of Patients With Inflammatory Bowel Disease Receiving Treatment With Anti\u2010TNF Alpha: 5\u2010Year Follow\u2010Up Study","volume":"42","author":"Pugliese D.","year":"2015","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"4","key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/MIB.0000000000000757","article-title":"Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti\u2010TNF Therapy in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study","volume":"22","author":"Guerra I.","year":"2016","journal-title":"Inflammatory Bowel Diseases"},{"key":"e_1_2_12_10_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02746","article-title":"Psoriasis: Classical vs. Paradoxical. The Yin\u2010Yang of TNF and Type I Interferon","volume":"9","author":"Mylonas A.","year":"2018","journal-title":"Frontiers in Immunology"},{"key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/978-1-0716-1130-2_11","article-title":"Experimental Methods for the Immunological Characterization of Paradoxical Psoriasis Reactions Induced by TNF\u2010\u03b1 Biologics","volume":"2248","author":"Morelli M.","year":"2021","journal-title":"Methods in Molecular Biology"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20617"},{"issue":"4","key":"e_1_2_12_13_1","doi-asserted-by":"crossref","DOI":"10.5826\/dpc.1404a250","article-title":"Anti\u2010IL\u201017\/23 Drugs for the Treatment of Moderate\u2010To\u2010Severe Hidradenitis Suppurativa in Patients With Concomitant Psoriasis: A Multicenter Retrospective Study","volume":"14","author":"Gargiulo L.","year":"2024","journal-title":"Dermatology Practical & Conceptual"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.10244"},{"issue":"1","key":"e_1_2_12_15_1","first-page":"1","article-title":"Elastic Net Regularization Paths for All Generalized Linear Models","volume":"106","author":"Tay J. K.","year":"2023","journal-title":"Journal of Statistical Software"},{"issue":"3","key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v045.i03","article-title":"Mice: Multivariate Imputation by Chained Equations in R","volume":"45","author":"Buuren S. V.","year":"2011","journal-title":"Journal of Statistical Software"},{"issue":"5","key":"e_1_2_12_17_1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/bjd.21716","article-title":"Paradoxical Reactions and Biologic Agents: A French Cohort Study of 9303 Patients","volume":"187","author":"Bataille P.","year":"2022","journal-title":"British Journal of Dermatology"},{"key":"e_1_2_12_18_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.594735","article-title":"The IL\u201023\/IL\u201017 Pathway in Inflammatory Skin Diseases: From Bench to Bedside","volume":"11","author":"Liu T.","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"6","key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/jdv.14125","article-title":"Efficacy and Safety of Interleukin\u201017 Antagonists in Patients With Plaque Psoriasis: A Meta\u2010Analysis From Phase 3 Randomized Controlled Trials","volume":"31","author":"Wu D.","year":"2017","journal-title":"Journal of the European Academy of Dermatology and Venereology"},{"issue":"8","key":"e_1_2_12_20_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0220868","article-title":"Assessing the Relative Efficacy of Interleukin\u201017 and Interleukin\u201023 Targeted Treatments for Moderate\u2010To\u2010Severe Plaque Psoriasis: A Systematic Review and Network Meta\u2010Analysis of PASI Response","volume":"14","author":"Sawyer L. M.","year":"2019","journal-title":"PLoS One"},{"issue":"11","key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/1744666X.2020.1679625","article-title":"Anti IL\u201017 in Psoriasis","volume":"15","author":"Ly K.","year":"2019","journal-title":"Expert Review of Clinical Immunology"},{"issue":"3","key":"e_1_2_12_22_1","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","article-title":"IL\u201017A Inhibition by Secukinumab Induces Early Clinical, Histopathologic, and Molecular Resolution of Psoriasis","volume":"144","author":"Krueger J. G.","year":"2019","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"3","key":"e_1_2_12_23_1","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jaci.2019.10.041","article-title":"Short\u2010Term Transcriptional Response to IL\u201017 Receptor\u2010A Antagonism in the Treatment of Psoriasis","volume":"145","author":"Tomalin L. E.","year":"2020","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"2","key":"e_1_2_12_24_1","doi-asserted-by":"crossref","first-page":"138","DOI":"10.36849\/JDD.2020.4645","article-title":"Clinical and Molecular Effects of Interleukin\u201017 Pathway Blockade in Psoriasis","volume":"19","author":"Green L.","year":"2020","journal-title":"Journal of Drugs in Dermatology"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.14592"},{"issue":"1","key":"e_1_2_12_26_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cytogfr.2014.10.009","article-title":"An Inflammatory Triangle in Psoriasis: TNF, Type I IFNs and IL\u201017","volume":"26","author":"Grine L.","year":"2015","journal-title":"Cytokine & Growth Factor Reviews"},{"key":"e_1_2_12_27_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.588382","article-title":"Interleukin\u201017A Facilitates Chikungunya Virus Infection by Inhibiting IFN\u2010\u03b12 Expression","volume":"11","author":"Neupane B.","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"8","key":"e_1_2_12_28_1","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.4049\/jimmunol.1800147","article-title":"IL\u201017A Attenuates IFN\u2010\u03bb Expression by Inducing Suppressor of Cytokine Signaling Expression in Airway Epithelium","volume":"201","author":"Niwa M.","year":"2018","journal-title":"Journal of Immunology"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555\u2010025\u201001364\u20108"},{"issue":"2","key":"e_1_2_12_30_1","doi-asserted-by":"crossref","DOI":"10.1111\/exd.15026","article-title":"Increased Neutrophil\u2010Derived IL\u201017A Identified in Generalized Pustular Psoriasis","volume":"33","author":"Lan Y.","year":"2024","journal-title":"Experimental Dermatology"},{"issue":"10378","key":"e_1_2_12_31_1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in Moderate\u2010To\u2010Severe Hidradenitis Suppurativa (SUNSHINE and SUNRISE): Week 16 and Week 52 Results of Two Identical, Multicentre, Randomised, Placebo\u2010Controlled, Double\u2010Blind Phase 3 Trials","volume":"401","author":"Kimball A. B.","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"e_1_2_12_32_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103818","article-title":"The Role of Interleukin Inhibitors in the Treatment of Hidradenitis Suppurativa; a Systematic Review of Clinical Trials","volume":"24","author":"Heidari N.","year":"2025","journal-title":"Autoimmunity Reviews"},{"issue":"4","key":"e_1_2_12_33_1","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2133.2006.07389.x","article-title":"A Study Examining Inter\u2010 and Intrarater Reliability of Three Scales for Measuring Severity of Psoriasis: Psoriasis Area and Severity Index, Physician's Global Assessment and Lattice System Physician's Global Assessment: Validation of PASI, PGA and LS\u2010PGA","volume":"155","author":"Berth\u2010Jones J.","year":"2006","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"e_1_2_12_34_1","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","article-title":"Joint AAD\u2013NPF Guidelines of Care for the Management and Treatment of Psoriasis With Topical Therapy and Alternative Medicine Modalities for Psoriasis Severity Measures","volume":"84","author":"Elmets C. A.","year":"2021","journal-title":"Journal of the American Academy of Dermatology"},{"key":"e_1_2_12_35_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1341632","article-title":"Application of JAK Inhibitors in Paradoxical Reaction Through Immune\u2010Related Dermatoses","volume":"15","author":"Zhang Y.","year":"2024","journal-title":"Frontiers in Immunology"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.70420","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.70420","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.70420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:39:35Z","timestamp":1776231575000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.70420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":34,"alternative-id":["10.1111\/ijd.70420"],"URL":"https:\/\/doi.org\/10.1111\/ijd.70420","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"2025-12-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"ijd.70420"}}